Chembio Diagnostics Inc., of Medford, N.Y., elected Katherine Davis to its board.

Cougar Biotechnology Inc., of Los Angeles, appointed Arturo Molina senior vice president of clinical research and development, and Christopher Haqq senior director of clinical research and development.

DiaKine Therapeutics Inc., of Charlottesville, Va., added Alexander Fleming to its scientific advisory board.

Emergent BioSolutions Inc., of Rockville, Md., said President Daniel Abdun-Nabi will take on the additional role of chief operating officer. Emergent also promoted R. Don Elsey to senior vice president finance and administration; it appointed Kyle Keese senior vice president corporate affairs; and said Thomas Zink is assuming responsibility for clinical development in addition to medical affairs.

Halozyme Therapeutics Inc., of San Diego, named Randal Kirk and Kathryn Falberg to its board.

InNexus Biotechnology Inc., of Vancouver, British Columbia, added John Minna to its scientific advisory board.

IR BioSciences Holdings Inc., of Scottsdale, Ariz., appointed Lance Gordon to its board.

Neurobiological Technologies Inc., of Edgewater, N.J., hired Vicki Higham as clinical project manager.

Nucryst Pharmaceuticals, of Wakefield, Mass., appointed Thomas Gardner to its board.

Numira Biosciences, of Irvine, Calif., hired Anthony Purchio as chief scientific officer.

QLT Inc., of Vancouver, British Columbia, elected Philip Livingston to its board.

Resverlogix Corp., of Calgary, Alberta, appointed Roger Newton to its board.

Serenex Inc., of Durham, N.C., appointed Judith Bryson vice president, clinical development.

SinoBiomed Inc., of Shanghai, China, added Zhi-Xin Wang to its board.